Earlier, approaches used for blood collection were invasive, time consuming and needed a healthcare expert. However, in recent years, the methods for blood collection are evolving at a rapid pace. According to research study, 69% of participant were found to take part more likely in clinical trials, if they are able to provide self-collected sample (at-home blood collection).
Recent Expansions: At-Home Blood Collection and Micro Sampling Devices
During our research we have observed that Everlywell is the most prominent player in this domain. In 2021, the company has made few acquisitions and also signed a distribution agreement. The company has also raised maximum amount of funds during period of time between 2013-2021.
Financial Expectations: At-Home Blood Collection and Micro Sampling Devices
The growing popularity of this domain has attracted several private / public investors for putting in funds for advancement of at-home blood collection and micro sampling. The total amount invested in this domain in the given time period between 2013 and 2021 was more than USD 600 million. The overall trend of investment in this domain has been very promising. It is worth highlighting that more than 60% of the total investment was raised by venture capital fundings.
Cost Saving Potential of At-Home Blood Sampling and Micro Sampling Devices
At-home blood collection and micro sampling devices is a cost-efficient way of sampling for patient and healthcare as well. It reduces cost of phlebotomist as the patient itself would draw blood and sent it to lab. Patients who needs a regular blood monitoring can save cost, by saving time required for sampling, patient can also save expense such as, travelling to lab, parking and other expenses.
For further information on this domain, check out the report –